Presentation TCT 2015 TCT 69: Impact of Stage 5 Chronic Kidney Disease in Patients Undergoing Percutaneous or Surgical Carotid Artery Revascularization Insights of the Healthcare Cost and Utilization Project's National Inpatient Sample Presenter: Mark C. Bates, Mark H. Wholey, Fabio Lima October 13, 2015
News Conference News TCT 2015 DISCOVER Registry: Positive Results Seen for Next-Generation TAVR Device at 1 Year October 12, 2015
News Conference News TCT 2015 Asian TAVR Registry Shows Good Procedural and Clinical Results October 11, 2015
News Daily News In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers October 01, 2015
News Daily News La Depresión Hemodinámica se asoció a la Lesión Renal Post-CAS en Pacientes con Enfermedad Renal L.A. McKeown September 28, 2015
News Daily News Hemodynamic Depression Tied to Kidney Injury After CAS in Patients With Renal Disease L.A. McKeown September 28, 2015
Presentation AKI in Patients With Chronic Kidney Disease Undergoing Internal CAS Implantation Presenter: M. Donahue September 25, 2015
News Industry News Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor August 31, 2015
News Industry News Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure August 31, 2015
News Daily News A-fib, Whether Preexisting or New-Onset, Tied to Poor Outcomes in TAVR Yael L. Maxwell August 30, 2015
News Daily News Real-World LVAD Use Promising in Patients Otherwise Considered Too Sick for PCI L.A. McKeown August 24, 2015
News Industry News Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease August 14, 2015
News Daily News El Método Elegido para Calcular la Función Renal Pre-PCI es Relevante L.A. McKeown June 29, 2015
News Industry News Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority June 22, 2015